News
Updated and committed to information
PEMBROLIZUMAB PLUS CHEMOTHERAPY IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER
Javier Cortes and his research team have conducted a clinical trial, currently in phase 3, to study the effect of adding pembrolizumab to standard chemotherapy
DIAGNOSIS AND MANAGEMENT OF AML IN ADULTS: 2022 ELN RECOMMENDATIONS FROM AN INTERNATIONAL EXPERT PANEL
The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized
ADAGRASIB FOR PATIENTS WITH ADVANCED LUNG CANCER WITH KRAS G12C MUTATION
Adagrasib is a KRAS G12C mutation inhibitor that has been studied for the past several years in patients with these mutations. This drug is similar
IMMUNOTHERAPY SHOWS 100% RESPONSE RATE IN CERTAIN RECTAL CANCER PATIENTS
Rectal cancer, a rare neoplasm related to colon cancer, is usually diagnosed at an advanced stage, when it is more difficult to treat. The standard
IBSAL SCIENTISTS PREDICT PROGNOSIS LUNG CANCER PATIENTS BY STUDYING A SPECIFIC GENE
Researchers from the Molecular Pathology research group at the Institute of Biomedical Research of Salamanca (IBSAL), led by Mª Dolores Ludeña, professor at the University
FDA APPROVES TRASTUZUMAB DERUXTECAN FAM-TRASTUZUMAB DERUXTECAN-NXKI FOR BREAST CANCER
On May 4, 2022, the Food and Drug Administration (FDA) approved Enhertu (trastuzumab deruxtecan) treatment from Daiichi Sankyo Company and AstraZeneca, for adult patients with
